Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist
Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adrenoleukodystrophy (X-ALD)
Potential for seven years of marketing exclusivity in the USA upon approval in the orphan designation indication

Can't see this document? Click Here